Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Wins Ratiopharm For $5 Billion, And Gains A Key Foothold In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

The acquisition makes Teva the leading generics company in Europe, which is a key to its ambitious plans for global growth.

You may also be interested in...



Teva CEO Offers Small Insights Into Big Priorities As Run Up to Dec. 11

Teva CEO Jeremy Levin provided additional glimpses of the company’s new strategy on a Q3 earnings call in advance of an investor meeting on Dec. 11, where he and Teva management will reveal their full agenda. Levin again put the emphasis on “focus” and “discipline” over “pure growth,” confirmed the company’s ‘confidence in the MS drug laquinimod, and highlighted several senior management appointments that reflect Teva’s new priorities.

Germany's Stada Strengthens Central, Eastern European Focus With Brand, Generic Buys

Stada spends $537 million on Grünenthal's branded product portfolio in Central and Eastern Europe and Spirig's generics business in Switzerland.

North American Buyers Turn to European Branded Generics For Growth

Europe's tough pricing and reimbursement environment may make it a graveyard for growth in innovative drugs, but there's still plenty of upside in generics, particularly of the branded, specialist kind.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel